EACSGE
27.1.2020 18:26:12 CET | Business Wire | Press release
From February 13th to 14th , the Royal Hotel Carlton in Bologna will be venue of the first edition of the international congress organized by the EACSGE (Esophageal Adenocarcinoma Study Group Europe ), dedicated to basic and clinical research, diagnosis and therapy of gastroesophageal junction adenocarcinoma and Barrett's esophagus (a pathology secondary to gastroesophageal reflux disease, which can lead to esophageal adenocarcinoma).
The initiative is promoted by the EACSGE and coordinated by Sandro Mattioli , Professor at Alma Mater Studiorum - University of Bologna, Director of Thoracic Surgery and the Esophageal Diseases Center at Maria Cecilia Hospital (GVM Care & Research) in Cotignola (Ravenna, Italy) and Prof. Sheila K. Krishnadath of the University Medical Center in Amsterdam (Netherlands).
"For the first time, in the scientific world, basic researchers and clinical specialists in Medical Genetics, Anatomic Pathology, Gastroenterology, Surgery and Oncology will discuss and transform the results obtained in basic research into clinical applications, – Prof. Mattioli explains – in order to make advances in the treatment of esophageal adenocarcinoma , which is now the sixth most frequent cancer in the Western world".
The EACSGE boasts multidisciplinary teams from the Universities of Genoa, Helsinki and Verona, the Vita-Salute University and the European Institute of Oncology in Milan, and the Oncology Institute Research Hospital in Meldola (FC).
The main objectives of the meeting include taking stock of the current state of knowledge on the biology of the disease, determining the predictors of field cancerization in Barrett's esophagus, in order to implement targeted surveillance protocols and evaluating the efficacy of vaccines that show promise in being able to halt the field cancerization process.
The discussion among experts may provide knowledge that can be used to modulate surgical and pharmacological therapies at every stage of the disease. Finally, during the conference, meetings will be held among members of the EACSGE and the event’s Faculty, aimed at expanding the study groups and preparing new research protocols.
There is also space devoted to the future of research: young researchers will have the opportunity to deliver a short presentation on the scientific progress of their studies; the most accurate report will also receive an accolade from the Scientific Committee and the organizers.
The complete event schedule is available at this link: https://www.iec-srl.it/index.php/it/eventi-2020/201-traslational-reserach-for-tha-management-of-barrett-s-esophagus-and-esophageal-adenocarcinoma
View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005551/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom